Your full article (between 500 to 5000 words) -- Do check for grammatical errors or spelling mistakes

# **CRISPR/Cas Technology: A Novel Approach for Plant Genome Modification**

#### Vyomesh S. Patel\*, Jalpesh S. Patel and Y. M. Shukla

Department of Biochemistry, BACA, Anand Agricultural University, Anand-388110, India. \*Email: vyomeshpatel@yahoo.com

### Abstract:

Cultivar development through plant breeding has reached to new horizon of transgenic technology to meet the current need for the crop development. CRISPR/Cas technology has made a breakthrough in the field of genome editing which has added new stars in transgenic technology. This article mainly deals with basic concept of CRISPR/Cas technology and its mechanism along with various types of CRISPR/Cas system. Advantage of CRISPR/Cas technology over other existing tools for genome editing has also been outlined. Applications of CRISPR/Cas technology in genome editing also has been summarized at the end of this article.

### Introduction:

Genome editing of model organisms is essential for gene function analysis and is thus critical for human health and agricultural production. The current technologies used for genome modification include ZFN (zinc-finger nuclease), meganucleases, TALEN (Transcription activator- like effecter nucleases), *etc.* Recently, a new technology for genome modification, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/ Cas (CRISPR-associated) systems, has been developed. CRISPR/Cas systems are adaptive defense systems in prokaryotic organisms to fight against alien nucleic acids. Compared with protein-guided technologies like ZFN and TALEN, CRISPR/Cas system is much easier to implement, as only short guide RNAs need to be customized to target the genes of interest. Up to now, the CRISPR/Cas system has been successfully applied to efficient genome editing in many eukaryotic organisms including human, mice, zebra fish, fly, worm, yeast and few plants. (Miao *et al.*, 2013).

#### Mechanism of CRISPR/Cas System:

CRISPR–Cas system recognizes and targets the alien genetic material through stepwise processes, namely acquisition, expression, and interference. The **acquisition** process involves recognition and integration of foreign DNA as spacer within the CRISPR locus. In the **second step**, *i.e.* **expression**, the long pre-crRNA is actively transcribed from the CRISPR locus and processed into crRNAs with the

help of Cas proteins (Cas1, Cas2, Cas9, and Cas4/Casn2) and the tracr-RNA molecule. The tracr-RNA pairs with the repeat region of crRNA via base complementarity and the processed crRNAs enter into the CRISPR-associated complex for antiviral defence (CASCADE). During the **interference step**, the crRNA guides the Cas protein complex to the specific target region of the foreign DNA for cleavage and provides immunity against pathogen attacks (Kumar and Jain, 2014).




Figure 1. Cas9 in vivo: Bacterial Adaptive Immunity (Jinek et al., 2012)

# **Types of CRISPR - Cas Systems**

Based on this classification that integrates phylogeny, sequence, locus organization, and content, three types have been distinguished, Type I, Type II, and Type III CRISPR-Cas systems.

# Type I CRISPR-Cas System


In addition to the presence of the conserved Cas1 and Cas2 proteins, Type I is defined by the ubiquitous presence of a **signature protein**, **the Cas3** helicase/nuclease. Cas3 is a large multi domain protein with distinct DNA nuclease and helicase activities. In addition, there are multiple Cas proteins that form CASCADE-like complexes that are involved in the interference step. The Type I CRISPR-Cas system in *E. coli* is one of the best characterized.

### **Type II CRISPR-Cas System**

This system is typified by the **Cas9 signature protein**, a large multifunctional protein with the ability to generate crRNA, as well as target phage and plasmid DNA for degradation. Cas9 appears to contain two nuclease domains, one at the N terminus (RuvC-like nuclease) and an HNH (McrA-like) nuclease domain in the middle section (which might be involved in target cleavage based on its endonuclease activity). The best-studied Type II system is that of *Streptococcus thermophilus*, which has been shown to provide defence against bacteriophage and plasmid DNA.

# **Type III CRISPR-Cas System**

This system has a number of recognizable features, including the **signature RAMP protein**, **Cas10**, which is likely involved in the processing of crRNA and possibly also in target DNA cleavage, and is somewhat functionally analogous to the Type I CASCADE. The Type III system also contains the **signature Cas6**, involved in crRNA processing and additional RAMP proteins likely to be involved in crRNA trimming. The universal cas1 and cas2 genes are mostly in operon-like structures with the rest of the cas genes but are not always in the same operon as the RAMP proteins in the Type III systems. So far, two type III systems have been distinguished (Type IIIA and IIIB). In *Pyrococcus furiosus*, a Type IIIA system, the target of CRISPR interference is mRNA, whereas in *Staphylococcus epidermidis*, a Type IIIB system, the target is DNA.



#### Difficulties with existing technology

- Both *ZFNs* and *TALENs* have tandem repeats in their DNA-binding domains that can be engineered to recognize specific DNA sequences
- The resulting chimeric nucleases can thus be **guided through protein** to the desired target sequences in the genome to generate DSBs
- Hence, a new ZFN or TALEN chimeric **protein** needs to be **engineered** for every new target
- This has been a major hurdle in the wide use of these two gene-editing systems because engineering a new protein is no trivial task
- *Costly:* ZFN or TALENs are much more expensive
- *Reliability:* Skip bases, off target toxicity
- *Long Turn-over Time:* Difficult to Scale up, ZFN : Several weeks to build a few pairs for expert, TALEN : One week to build a few pairs

#### Advantages of CRISPR over Other


- By contrast, *Cas9* is a nuclease guided by small RNAs through Watson-Crick base pairing with target DNA, Hence,
- Easier to design and highly specific
- Efficient and well-suited for high-throughput
- Multiplexed gene editing is possible for a variety of cell types and organisms
- So only a new sgRNA is needed for a new target site

<u>RNAi</u>	<u><i>CRISPRi</i></u> • Target/Object:	
• Target/Object:		
➢ RNA (post-transcriptional control)	DNA (transcriptional control)	
RNA Degradation	<ul> <li>Block transcription initiation or transcription elongation</li> </ul>	
Object(s) in cytoplasm	<ul> <li>Both template and non-template strands</li> <li>Object(s) in nucleus</li> </ul>	
	Design/Construct:	
	Easy and flexible	
	Design algorithm available	
	PAM dependence limited its target sequence	
	• Efficiency:	
Design/Construct:	➤ Variable	
	Off-target effects (maybe less)	
plications of CRISPR/Cas System		
Genotyping of Microorganisms		
Building <i>Resistance to Viruses</i>		
• To obtain <i>phage-resistant mutan</i>	ts	
• To vaccinate bacterial strains		
Genome Engineering		
• Gene Therapy		

• To label *specific chromosomal loci* in living cells or organisms

Outline of generating a CRISPR/Cas9-mutagenised plant line (Belhaj et al., 2015)

#### Authors: Vyomesh S. Patel\*, Jalpesh S. Patel and Y. M. Shukla



#### Authors: Vyomesh S. Patel\*, Jalpesh S. Patel and Y. M. Shukla

B2m	95	Rattus norvegicus, Mus musculus
YSA	92	Oryza sativa
Tet2	88	Rattus norvegicus, Mus musculus
DDM1	87	Glycine max
CCR5	86	Homo sapiens
PCSK9	81	Mus musculus
DMD	80	Homo sapiens
Fh	72	Danio rerio
Pcdh	72	Homo sapiens
HBB	70	Homo sapiens
PDS3	66	Arabidopsis thaliana, Nicotiana benthamiana

### **Conclusion:**

- The CRISPR/Cas9 technology is versatile method for efficient genome modification of eukaryotes and found useful to study the effect of genome modification on plants through the gene knockout technique.
- The CRISPR/Cas9 system requires only the redesigning of the crRNA which makes it **far convenient** and **more promising** as compare to ZFN and TALEN.
- It has been successfully used in various crop plants like rice, wheat, sweet orange, tomato, etc.; for the development of mutagenised plant lines through genome modification to improve quality parameters.

# **Future Thrust:**

- More efficient CRISPR system should be identified, characterised and developed for better utility and **expanding the targeting range** of RNA-guided Cas9.
- The field urgently needs to develop unbiased strategies to globally assess the **off-target effects** of Cas9 nucleases or paired nickases.
- Multiplex genome modification strategies should be developed
- Efforts should be initiated to improve crop plants for **biotic stress resistance**, **nutritional quality** *etc...*

#### References

- 1. Barrangou R and Marraffini LA. 2014. CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity. *Molecular Cell* **54**: 234-244.
- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, and Horvath P. 2007. CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 315: 1709–1712.
- 3. Belhaj K, Chaparro-Garcia A, Kamoun S, Patron NJ and Nekrasov V. 2015. Editing plant genomes with CRISPR/Cas9. *Current Opinion in Biotechnology* **32:** 76–84.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 337: 816-821.
- 5. Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, *et al.* 2014. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. *Science* **343**: 1247997.
- 6. Kaur K, Tandon H, Gupta AK and Kumar M.\* 2015. CrisprGE: a central hub of CRISPR/Casbased genome editing. *Database*, 1–8.
- 7. Kumar V and Jain M. 2014. *Journal of Experimental Botany* doi:10.1093/jxb/eru429.
- 8. Miao J, Guo D, Zhang J, Huang Q, Qin G, Zhang X, Wan J, Gu H and Qu L-J. 2013. Targeted mutagenesis in rice using CRISPR-Cas system. *Cell Res.* **23**: 1233-1236.

#### References (if any)

1. 2.

# Terms - Do not remove or change this section (It should be emailed back to us as is)

- This form is for genuine submissions related to biotechnology topics only.
- You should be the legal owner and author of this article and all its contents.
- If we find that your article is already present online or even containing sections of copied content then we treat as duplicate content such submissions are quietly rejected.

• If your article is not published within 3-4 days of emailing, then we have not accepted your submission. Our decision is final therefore do not email us enquiring why your article was not published. We will not reply. We reserve all rights on this website.

• Do not violate copyright of others, you will be solely responsible if anyone raises a dispute regarding it.

• Similar to paper based magazines, we do not allow editing of articles once they are published. Therefore please revise and re-revise your article before sending it to us.

• Too short and too long articles are not accepted. Your article must be between 500 and 5000 words.

 We do not charge or pay for any submissions. We do not publish marketing only articles or inappropriate submissions.

• Full submission guidelines are located here: http://www.biotecharticles.com/submitguide.php

• Full Website terms of service are located here: http://www.biotecharticles.com/privacy.php

As I send my article to be published on BiotechArticles.com, I fully agree to all these terms and conditions.